Amnioreduction as a therapeutic strategy for MAGED2-related Bartter syndrome: prolonging gestation and improving outcomes through genetic-guided prenatal management
Amnioreduction mitigates polyhydramnios-driven preterm birth in MAGED2 -related Bartter syndrome, enabling safer gestational prolongation. Integration of WES for rapid genetic diagnosis and multidisciplinary care optimizes prenatal management. These findings support amnioreduction as a critical intervention for this high-risk population, emphasizing early genetic testing, and proactive fetal therapy.
Authors
- Caiqun Luo (ORCID: https://orcid.org/0009-0006-3038-0931)
- Xue-Lin Cao
- Yang Liu (ORCID: https://orcid.org/0000-0001-9605-7877)
- Hui Wang (ORCID: https://orcid.org/0000-0002-5208-8329)
- Liyuan Chen (ORCID: https://orcid.org/0000-0002-2964-2555)
- Xiaoxia Wu (ORCID: https://orcid.org/0000-0002-1545-414X)
Institutions
- Society for Maternal-Fetal Medicine (US)
- Shenzhen Maternity and Child Healthcare Hospital (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- Clinical Dysmorphology
- Published
- 2025-07-04
- DOI
- https://doi.org/10.1097/mcd.0000000000000536
- Primary Topic
- Congenital heart defects research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sanming Project of Medicine in Shenzhen